<DOC>
	<DOCNO>NCT01603095</DOCNO>
	<brief_summary>Multicenter , multinational study collect consistent baseline growth measurement pediatric patient Achondroplasia consider subsequent enrollment Study 111-202 . No study drug administer .</brief_summary>
	<brief_title>A Multicenter , Multinational Clinical Assessment Study Pediatric Patients With Achondroplasia</brief_title>
	<detailed_description />
	<mesh_term>Achondroplasia</mesh_term>
	<criteria>Parent ( ) guardian ( ) willing able provide sign informed consent nature study explain prior performance researchrelated procedure . Also , willing able provide write assent ( need ) nature study explain prior performance researchrelated procedure . Aged 2 13.5 year , inclusive , study entry . Patients age 0 &lt; 2 year date consent may also enrol , time discretion sponsor . Have ACH , document clinical diagnosis Are ambulatory able stand without assistance ( applicable infant ) Are willing able perform study procedure physically possible . Have hypochondroplasia short stature condition ACH ( e.g. , trisomy 21 , pseudoachondroplasia ) Have follow disorder : Hypothyroidism Insulinrequiring diabetes mellitus Autoimmune inflammatory disease Inflammatory bowel disease Autonomic neuropathy Have unstable clinical condition likely lead intervention course study , include progressive cervical medullary compression Growth plat fuse Have history follow : Renal insufficiency Anemia Cardiac vascular disease , include follow : Cardiac dysfunction ( abnormal echocardiogram [ ECHO ] include leave ventricle [ LV ] mass ) Screening Visit Hypertrophic cardiomyopathy Congenital heart disease Cerebrovascular disease , aortic insufficiency Clinically significant atrial ventricular arrhythmias Current treatment antihypertensive medication , ACE inhibitor , angiotensin II receptor blocker , diuretic , betablockers , calciumchannel blocker , cardiac glycoside , systemic anticholinergic agent , medication may impair enhance compensatory tachycardia , drug know alter renal function expect continue duration study Have treat growth hormone , insulinlike growth factor 1 ( IGF1 ) , anabolic steroid previous 6 month longterm treatment ( &gt; 3 month ) time Have regular longterm treatment ( &gt; 1 month ) oral corticosteroid ( lowdose ongoing inhaled steroid asthma acceptable ) Concomitant medication prolongs QT/QTc interval within 14 day 5 halflives , whichever longer , Screening visit Have use investigational product investigational medical device treatment ACH short stature Have bonerelated surgery expect bonerelated surgery study period . Subjects previous limblengthening surgery may enroll surgery occur least 18 month prior study heal complete without sequela . Have condition , view Investigator , place patient high risk poor compliance visit schedule complete study . Concurrent disease condition , view Investigator , would interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Achondroplasia</keyword>
	<keyword>dwarfism</keyword>
</DOC>